RHEUMATOID ATHRITIS

CAMERA

Intensive treatment with methotrexate in early rheumatoid arthritis

Benefitial

tREACH

Induction therapy with a combination of DMARDs is better than methotrexate monotherapy

Triple DMARD induction therapy is better than MTX monotherapy in early RA

SELECT-CHOICE

Upadacitinib or Abatacept in Rheumatoid Arthritis

In patients with rheumatoid arthritis refractory to biologic DMARDs, upadacitinib was superior to abatacept in the change from baseline in the DAS28-CRP and the achievement of remission at week 12 but was associated with more serious adverse events. Longer and larger trials are required in order to determine the effect and safety of upadacitinib in patients with rheumatoid arthritis.

Efficacy of tocilizumab in patients with hand osteoarthritis: double blind, randomised, placebo-controlled, multicentre trial

Tocilizumab was no more effective than placebo for pain relief in patients with hand osteoarthritis.

ARCTIC REWIND

Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission

Among patients with RA in remission taking csDMARD therapy, treatment with half-dose vs stable-dose csDMARDs did not demonstrate noninferiority for the percentage of patients with disease flares over 12 months, and there were significantly fewer flares in the stable-dose group.

These findings do not support treatment with half-dose therapy.

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases